| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 2,829 | -76 |
| Net decrease in cash and cash equivalents | -13,219 | -10,644 |
| Cash and cash equivalents at beginning of period | 20,020 | - |
| Cash and cash equivalents at end of period | 6,801 | - |
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. (CLSD)